Researchers at UVA developed an AI imaging tool using PET/MR to distinguish treatment effects from tumor progression in glioblastoma patients.
Key Details
- 1AI tool analyzes PET/MR imaging findings in glioblastoma cases.
- 2Distinguishes between tissue changes due to treatment vs. tumor progression.
- 3Current monitoring approaches often require a waiting period of 3+ months.
- 4Faster distinction could enable earlier treatment modification for recurrence.
- 5Method developed by a University of Virginia team.
Why It Matters
Improved differentiation between treatment effects and recurrence could allow clinicians to adjust therapies more quickly, potentially improving outcomes for a highly aggressive brain cancer. This underlines the growing significance of AI-assisted multi-modal imaging in oncology workflows.
Source
Health Imaging
Related News
•AI in Healthcare
Literature Review Highlights Gaps in Economic Evaluation of Healthcare AI
A Finnish review finds significant gaps in economic evaluation reporting of AI technologies in Western healthcare.
•AI in Healthcare
Economic Evaluations of AI in Healthcare Face Major Gaps
A Finnish review finds significant deficiencies in how studies evaluate and report the economic impact of healthcare AI.
•Health Imaging
AI Platform Triples Functional Independence in UK Stroke Patients
AI brain imaging software deployed by NHS has significantly improved stroke outcomes and functional independence rates in England.